Staphylococcus aureus alpha-hemolysin impairs corneal epithelial wound healing and promotes intracellular bacterial invasion.


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
04 2019
Historique:
received: 07 08 2018
revised: 20 02 2019
accepted: 21 02 2019
pubmed: 2 3 2019
medline: 14 2 2020
entrez: 2 3 2019
Statut: ppublish

Résumé

Colonization by Staphylococcus aureus (S. aureus) has been implicated in many infectious and wound healing disorders. This study was performed to characterize the pathogenic role of S. aureus alpha-hemolysin (alpha-toxin) in corneal epithelial wound healing and infectious keratitis in the setting of a corneal wound. The effect of wild-type and isogenic Hla mutant (α-hemolysin gene deleted) S. aureus bacteria and conditioned media on corneal epithelial wound healing was tested in vitro using a scratch assay and in vivo using a murine epithelial debridement model. The invasiveness of wild-type and Hla mutant S. aureus was evaluated in vitro in human corneal epithelial cells and in vivo in a murine model of infectious keratitis following total epithelial debridement. S. aureus and its conditioned media significantly delayed epithelial wound closure both in vitro (P < 0.05) and in vivo (P < 0.05). The effect of S. aureus on wound healing was significantly diminished with the Hla mutant strain (P < 0.05). Likewise, compared to the wild-type strain, the Hla mutant strain demonstrated significantly reduced ability to invade corneal epithelial cells in vitro (P < 0.05) and infect murine corneas following total epithelial debridement in vivo (P < 0.05). In conclusion, S. aureus alpha-hemolysin plays a major role in the pathologic modulation of corneal epithelial wound healing and the intracellular invasion of the bacteria. Limiting colonization by S. aureus and/or blocking alpha-hemolysin may provide a therapeutic approach for corneal wound healing and infectious disorders.

Identifiants

pubmed: 30822400
pii: S0014-4835(18)30592-X
doi: 10.1016/j.exer.2019.02.019
pmc: PMC6447303
mid: NIHMS1523140
pii:
doi:

Substances chimiques

Hemolysin Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-270

Subventions

Organisme : NEI NIH HHS
ID : K12 EY021475
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY001792
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY024349
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

PLoS One. 2013 Jul 18;8(7):e69113
pubmed: 23874882
Immunol Lett. 2013 Feb;150(1-2):12-22
pubmed: 23376548
Infect Immun. 2006 Sep;74(9):5325-32
pubmed: 16926427
Am J Clin Pathol. 1973 Aug;60(2):234-40
pubmed: 4124318
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2496-506
pubmed: 12766048
Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):466-70
pubmed: 19620859
ILAR J. 1999 Mar;40(2):43-50
pubmed: 11309524
J Infect Dis. 2014 Sep 1;210(5):784-92
pubmed: 24620023
JAMA Ophthalmol. 2015 Dec;133(12):1445-54
pubmed: 26502312
Exp Eye Res. 2013 Dec;117:99-105
pubmed: 23797046
J Biol Chem. 2015 Jun 26;290(26):16157-67
pubmed: 25931123
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2064-70
pubmed: 15914624
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4926-30
pubmed: 17065508
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Sci Rep. 2015 Sep 14;5:14003
pubmed: 26365869
Infect Immun. 1997 May;65(5):1571-8
pubmed: 9125532
Infect Immun. 2005 Oct;73(10):6199-209
pubmed: 16177291
Invest Ophthalmol Vis Sci. 2012 Nov 01;53(12):7476-83
pubmed: 23049092
Clin Exp Ophthalmol. 2017 Mar;45(2):105-111
pubmed: 27473509
Cornea. 2015 Jun;34(6):698-703
pubmed: 25811722
Arq Bras Oftalmol. 2013 Nov-Dec;76(6):350-3
pubmed: 24510081
Am J Ophthalmol. 2014 Sep;158(3):420-2
pubmed: 25132249
Invest Ophthalmol Vis Sci. 2012 Aug 15;53(9):5585-93
pubmed: 22836761
Cochrane Database Syst Rev. 2012 May 16;(5):CD005556
pubmed: 22592706
Invest Ophthalmol Vis Sci. 2014 Sep 02;55(9):6108-15
pubmed: 25183764
Yale J Biol Med. 2016 Sep 30;89(3):325-330
pubmed: 27698616
Infect Immun. 1994 Jun;62(6):2478-82
pubmed: 8188373
Ophthalmology. 2002 May;109(5):835-42; quiz 843
pubmed: 11986084
J Biomed Biotechnol. 2011;2011:680642
pubmed: 21274270
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2848-54
pubmed: 19136695
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1591-7
pubmed: 12657597
Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2904-8
pubmed: 11687535
JAMA. 2007 Oct 17;298(15):1763-71
pubmed: 17940231
Clin Microbiol Rev. 2002 Jan;15(1):111-24
pubmed: 11781270
Cornea. 2008 Jan;27(1):22-7
pubmed: 18245962
Immunol Cell Biol. 2005 Jun;83(3):294-300
pubmed: 15877608
Ophthalmic Res. 2008;40(3-4):193-9
pubmed: 18421238
Eye Contact Lens. 2016 Nov;42(6):366-370
pubmed: 26657662

Auteurs

Ilham Putra (I)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Behnam Rabiee (B)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Khandaker N Anwar (KN)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Sanaz Gidfar (S)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Xiang Shen (X)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Mehrdad Babalooee (M)

Division of Infectious Diseases, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Suite 888 (MC 735), Chicago, IL, 60612, United States.

Mahmood Ghassemi (M)

Division of Infectious Diseases, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Suite 888 (MC 735), Chicago, IL, 60612, United States.

Neda Afsharkhamseh (N)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Saaquib Bakhsh (S)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Dominique Missiakas (D)

Department of Microbiology, University of Chicago, 920 East 58th St., CLSC 1117, Chicago, IL, 60637, United States.

Ali Nezamabadi (A)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Behrad Milani (B)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Medi Eslani (M)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States.

Ali R Djalilian (AR)

Stem Cell Therapy and Corneal Tissue Engineering Laboratory, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W. Taylor St., L-213, Chicago, IL, 60612, United States. Electronic address: adjalili@uic.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH